Indian drugmakers look beyond generics as Sun Pharma buys Organon

India's Sun Pharma is buying U.S.-based Organon for $11.75 billion in what is the largest overseas acquisition by a drugmaker from the South Asian country. © Reuters

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.